NEW YORK – The European Medicines Agency has given the green light to an investigator-initiated trial of Lantern Pharma's lead drug candidate LP-184 (zirdafulven) for advanced, recurrent bladder ...

The company closed an upsized IPO and concurrent private placement to Sanofi, proceeds of which will fund its pipeline of CRISPR-based medicines.

The firm's oncology unit reported 16 percent growth in Q2, with nearly all oncology medicines reporting revenue growth in the ...

NEW YORK – Estrella Immunopharma's first trial of its CD19-directed autologous T-cell therapy for non-Hodgkin's lymphoma is progressing smoothly, the company said late last week, and it has moved on ...

NEW YORK – Oak Hill Bio on Monday said it plans to go public through a merger with Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC), and raise funds to develop ...

The company is eyeing deals less than $2 billion, saying it has enough internal assets to replace losses from generic ...

Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...

Researchers at the Broad Institute, Jackson Laboratory, and Boston Children's Hospital will treat rare disease patients and ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended approval for AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug ...

The biotech plans to use the proceeds to develop its pipeline of in vivo CRISPR-based genetic medicines for cardiometabolic disease, including STX-1150.

It is also preclinically testing three RNA vaccines — one for cytomegalovirus-driven colorectal cancer, glioblastoma, and triple-negative breast cancer, a second for HPV-positive head and neck cancers ...

After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...